Accelerating technological advances have allowed the widespread genomic profiling of
tumors. As yet, however, the vast catalogues of mutations that have been identified have …

Advances in next-generation sequencing and bioinformatics have led to an unprecedented
view of the cancer genome and its evolution. Genomic studies have demonstrated the …

Defining the chronology of molecular alterations may identify milestones in carcinogenesis.
To unravel the temporal evolution of aberrations from clinical tumors, we developed …

Cancer genome projects are now being expanded in an attempt to provide complete
landscapes of the mutations that exist in tumours. Although the importance of cataloguing …

The efficacy of targeted therapies in leukemias and solid tumors depends upon the accurate
detection and sustained targeting of initial and evolving driver mutations and/or aberrations …

Recent technological advances in the field of molecular diagnostics (including blood-based
tumor genotyping) allow the measurement of clonal evolution in patients with cancer, thus …

Next-generation deep genome sequencing has only recently allowed us to quantitatively
dissect the extent of heterogeneity within a tumour, resolving patterns of cancer evolution …

Early successes in identifying and targeting individual oncogenic drivers, together with the
increasing feasibility of sequencing tumor genomes, have brought forth the promise of …

Human cancer is not a uniform disease but a plethora of disparate tumor types and
subtypes. The differences that exist between individual tumors (intertumoral heterogeneity) …

Recurring sequences of genomic alterations occurring across patients can highlight
repeated evolutionary processes with significant implications for predicting cancer …